Survival rates of cervical cancer patients in Sarawak: a single-centre referral study
- PMID: 40866851
- PMCID: PMC12382113
- DOI: 10.1186/s12885-025-14678-9
Survival rates of cervical cancer patients in Sarawak: a single-centre referral study
Abstract
Background: Cervical cancer represents a significant health challenge in Malaysia, especially in the state of Sarawak which records some of the highest incidence rates across the country. This study evaluates the survival rates of cervical cancer patients in Sarawak, focusing on demographic characteristics, disease stage and survival outcomes to inform healthcare strategies.
Methods: A retrospective case notes review of disease stage, patterns of care and survival outcomes of patients diagnosed with cervical cancer at Sarawak General Hospital between January 2018 to December 2022 was conducted. Kaplan-Meier survival analysis and Cox Regression analysis were performed to assess survival outcomes and factors influencing survival.
Results: A total of 555 patients were included in this review. The majority of patients were diagnosed between the ages of 40 and 59, with a mean age of 53 years. Ibans comprised the largest subgroup by ethnicity. Only 11.2% of patients were diagnosed with Stage I disease. The majority of patients were diagnosed at advanced stages III and IV. The overall 5-year survival rate was 59.4%. Factors significantly affecting survival included FIGO cancer stage and ethnicity.
Conclusions: Diagnosis at advanced stages of disease lead to poorer clinical outcomes in cervical cancer patients in Sarawak. This study highlights the critical need for enhanced screening and early diagnosis to improve survival rates amongst cervical cancer patients Sarawak. Efforts should focus on improving cervical health literacy, expanding access to healthcare services and improving the uptake of HPV vaccination and cervical screening particularly in rural communities.
Keywords: Cervical cancer; Epidemiology; Sarawak; Survival analysis.
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was approved by the Malaysia Medical Research and Ethics Committee (NMRR ID-23-01963-0MY; MREC Reference: 23-01963-0MY on 25 July 2023) waiving the need for informed consent as it is a retrospective data collection from available medical records. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures
References
-
- Cancer Today. 2020. Available from: https://gco.iarc.fr/today/home. [cited 2023 May 8].
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
-
- Global Cancer Observatory: Malaysia (2020). Available from: https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-.... Cited 2023 May 8.
-
- Department of Statistics Malaysia. Statistics on Causes of Death 2019. 2020. Available from: https://newss.statistics.gov.my/newss-portalx/ep/epLogin.seam. [cited Oct 2020].
-
- Galen Centre for Health and Social Policy. White Paper - Cancer Care Challenges, Gaps and Opportunities in Malaysia. Kuala Lumpur; 2021. Available from: https://www.phama.org.my/view_file.cfm?fileid=145. [cited 2022 Dec 28].
Grants and funding
LinkOut - more resources
Full Text Sources